Background: The presence of ascites has been considered a relative contraindication for performing percutaneous thermal ablation of hepatic tumors due to concerns for hemorrhage. The purpose of our study as to evaluate the incidence of post-procedure hemorrhage in patients ith ascites ho underent percutaneous thermal ablation of hepatic malignancy at our institution. We believe that the presence of ascites should not be a contraindication, especially given the efficacy of ablation in treating hepatic tumors. Methods: We performed a retrospective revie of 78 patients ho underent thermal ablation of the liver beteen 112014 and 9292015. Of these, 19 patients had imaging evidence of ascites at the time of their procedure  excluding those ith trace ascites . 4 of the 19 patients underent microave ablation tice during this time period. Thus, 23 total sessions of ablation ere evaluated. In order to assess for post-procedure hemorrhage, post-procedural vital signs, prepost ablation hemoglobin levels, hospital readmission statistics, and imaging ere revieed, if available. Results: Patients ranged in age from 55-86 years. All but to had a diagnosis of hepatocellular carcinoma. Mean preprocedure INR as 1.3 and mean platelet count as 82,000microliter. Most patients had Child-Pugh class B cirrhosis  one had class A and three had class C cirrhosis . All procedures ere performed ith Covedien Emprint or NeuWave Certus microave probes. 1-2 probes ere used in each case. The tract as cauterized during probe removal in all cases. There as no evidence of post-procedure hemorrhage in any of the 23 sessions of microave ablation. Conclusions: Percutaneous microave ablation of hepatic malignancy in patients ith ascites has been a safe treatment at our institution ith no post-procedure hemorrhage reported to date.,J Clin Oncol 34, 2016  suppl; abstr e15582 ,Publication Only Gastrointestinal  Noncolorectal  Cancer